Lipoprotein-associated phospholipase A2 predicts 5-year cardiac mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (The Ludwigshafen Risk and Cardiovascular Health Study)

Clinical Chemistry

Volumn 53, Issue 8, 2007, Pages 1440-1447

  Winkler, Karl ^a   Hoffmann, Michael M ^a   Winkelmann, Bernhard R ^b   Friedrich, Isolde ^a   Schäfer, Günther ^a   Seelhorst, Ursula ^c   Wellnitz, Britta ^c   Wieland, Heinrich ^a   Boehm, Bernhard O ^d   März, Winfried ^e  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Cardiology Group   (Germany)

^c LURIC Study Nonprofit LLC   (Germany)

^d UNIVERSITY HOSPITAL ULM   (Germany)

^e SYNLAB ACADEMY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; HIGH SENSITIVITY C REACTIVE PROTEIN; LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A2; PHOSPHOLIPASE A2; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CORONARY ARTERY DISEASE; CORONARY RISK; ENZYME ACTIVITY; FEMALE; HEART DEATH; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROGNOSIS; RISK FACTOR;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; C-REACTIVE PROTEIN; CORONARY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 34547614814     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2007.086298     Document Type: Article

References (37)

1. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
2. Koenig W, Lowel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 2004;109:1349-53.
3. Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004;109:2818-25.
4. Imaizumi TA, Stafforini DM, Yamada Y, Mclntyre TM, Prescott SM, Zimmerman GA. Platelet-activating factor: a mediator for clinicians. J Intern Med 1995;238:5-20.
5. Evangelou AM. Platelet-activating factor (PAF): implications for coronary heart and vascular diseases. Prostaglandins Leukot Essent Fatty Acids 1994;50:1-28.
6. Tjoelker LW, Stafforini DM. Platelet-activating factor acetylhydrolases in health and disease. Biochim Biophys Acta 2000;1488:102-23.
7. MacPhee CH, Moores KE, Boyd HF, Dhanak D, Ife RJ, Leach CA, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 1999;338:479-87.
8. Itabe H. Oxidized phospholipids as a new landmark in atherosclerosis. Prog Lipid Res 1998;37:181-207.
9. Karabina SA, Elisaf M, Bairaktari E, Tzallas C, Siamopoulos KC, Tselepis AD. Increased activity of platelet-activating factor acetylhydrolase in low-density lipoprotein subtractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia. Eur J Clin Invest 1997;27:595-602.
10. Karabina SA, Ninio E. Plasma PAF-acetylhydrolase: an unfulfilled promise? Biochim Biophys Acta 2006;1761:1351-8.
11. Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, MacPhee CH. Lipoprotein-associated phospholipase A2 platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 2000;150:413-9.
12. Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease: West of Scotland Coronary Prevention Study Group. N Engl J Med 2000;343:1148-55.
13. Blankenberg S, Stengel D, Rupprecht H, Bickel C, Meyer J, Cambien F, et al. Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis. J Lipid Res 2003;44:1381-6.
14. Koenig W, Khuseyinova N, Löwel H, Trischler G, Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 2004;110:1903-8.
15. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 2005;26:137-44.
16. Iribarren C, Gross MD, Darbinian JA, Jacobs DR Jr, Sidney S, Loria CM. Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study. Arterioscler Thromb Vasc Biol 2005;25:216-21.
17. Winkler K, Winkelmann BR, Scharnagl H, Hoffmann MM, Grawitz AB, Nauck M, et al. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study. Circulation 2005;111:980-7.
18. Winkler K, Abletshauser C, Friedrich I, Hoffmann MM, Wieland H, Marz W. Fluvastatin slow-release lowers PAF-AH activity: a placebo controlled trial in patients with type 2 diabetes. J Cin Endocrinol Metab 2004;89:1153-9.
19. Blake GJ, Dada N, Fox JC, Manson JE, Ridker PM. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol 2001;38:1302-6.
20. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004;109:837-42.
21. Koenig W, Twardella D, Brenner H, Rothenbacher D. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol 2006;26:1586-93.
22. Winkelmann BR, Marz W, Boehm BO, Zotz R, Hager J, Hellstern P, et al. Rationale and design of the LURIC study: a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics 2001;2:S1-73.
23. Austen WG, Edwards JE, Frye RL, Gensini GG, Gott VL, Griffith LSC, et al. A reporting system on patients evaluated for coronary artery disease: report of the Ad Hoc Committee for Grading of Coronary Artery Disease. Circulation 1975;51(Suppl 4):5-40.
24. Association AD. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
25. Kosaka T, Yamaguchi M, Soda Y, Kishimoto T, Tago A, Toyosanto M, et al. Spectrophotometric assay for serum platelet-activating factor acetylhydrolase activity. Clin Chim Acta 2000;296:151-61.
26. Kosaka T, Yamaguchi M, Miyanaga K, Mizuno K. Serum platelet-activating factor acetylhydrolase (PAF-AH) activity in more than 3000 healthy Japanese. Clin Chim Acta 2001;312:179-83.
27. Yang EH, McConnell JP, Lennon RJ, Barsness GW, Pumper G, Hartman SJ, et al. Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol 2006;26:106-11.
28. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Chambless LE, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 2005;165:2479-84.
29. Oei HH, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MM, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 2005;111:570-5.
30. Doust JA, Glasziou PP, Pietrzak E, Dobson AJ. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med 2004;164:1978-84.
31. de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345:1014-21.
32. Mega JL, Morrow DA, De Lemos JA, Sabatine MS, Murphy SA, Rifai N, et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. J Am Coll Cardiol 2004;44:335-9.
33. Jernberg T, James S, Lindahl B, Stridsberg M, Venge P, Wallentin L. NT-proBNP in unstable coronary artery disease: experiences from the FAST, GUSTO IV and FRISC II trials. Eur J Heart Fail 2004;6:319-25.
34. Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005;352:666-75.
35. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004;350:655-63.
36. Tuzcu EM, Kapadia SR, Tutar E, Ziada KM, Hobbs RE, McCarthy PM, et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation 2001;103:2705-10.
37. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003;289:2363-9.